Citigroup
NVCT icon

Citigroup’s Nuvectis Pharma NVCT Stock Holding History

Citigroup’s Portfolio NVCT Stock Details NVCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.37K Buy
824
+438
+113% +$3.75K ﹤0.01% 5192
2025
Q4 		$2.92K Sell
386
-160
-29% -$1.04K ﹤0.01% 5393
2025
Q3 		$3.29K Sell
546
-4,026
-88% -$27.7K ﹤0.01% 5354
2025
Q2 		$34.2K Buy
4,572
+3,547
+346% +$32.2K ﹤0.01% 4934
2025
Q1 		$10K Buy
+1,025
New +$7.38K ﹤0.01% 5200
2024
Q4 		– Sell
-8,887
Closed -$55.9K – 5913
2024
Q3 		$55.9K Buy
8,887
+4,004
+82% +$26.3K ﹤0.01% 4988
2024
Q2 		$30.9K Buy
4,883
+3,501
+253% +$23.8K ﹤0.01% 4850
2024
Q1 		$11.3K Buy
1,382
+274
+25% +$2.33K ﹤0.01% 5173
2023
Q4 		$9.24K Buy
1,108
+1,103
+22,060% +$9.84K ﹤0.01% 5209
2023
Q3 		$65 Sell
5
-2,034
-100% -$29.5K ﹤0.01% 5496
2023
Q2 		$32.6K Buy
+2,039
New +$32.5K ﹤0.01% 4827

Other funds holding NVCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
OCM
Occam Crest Management Darien, Connecticut $165M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BWP
Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Citigroup's NVCT Position: Q1 2026 in Review

Citigroup increased its Nuvectis Pharma (NVCT) stake by 113% in Q1 2026, buying an estimated $3.75K and bringing the position to 824 shares worth $6.37K. The position accounts for ﹤0.01% of the portfolio, ranked #5192.

Citigroup first reported a position in NVCT in Q2 2023 and has held it in 11 quarters since. The position peaked at $55.9K in Q3 2024. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

  • Citigroup held 824 shares of Nuvectis Pharma worth $6.37K as of Q1 2026.
  • Citigroup bought 438 Nuvectis Pharma shares in Q1 2026, an estimated $3.75K.
  • Nuvectis Pharma made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5192 holding.
  • Citigroup first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 11 quarters since.
  • Citigroup's Nuvectis Pharma position peaked at $55.9K in Q3 2024.
  • 62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.